PositiveID Corporation (fka PSID)

[Werbe]

"In 2017, we executed on a number of our goals in our mobile labs and medical device businesses, while continuing to pursue our long-term vision for our FireflyDX products, which includes finding the right strategic partner to complete the testing and development of the FireflyDX-Portable and FireflyDX-Handheld," stated William J. Caragol, PositiveID's Chairman and CEO. "Looking ahead, as we continue to build bookings within our mobile labs business and see a more robust sales pipeline for Caregiver, we believe we can deliver growth in excess of 30% for both the 2017 fourth quarter and 2018 first quarter, with continued strength expected through the first half of 2018 and beyond."

PositiveID, through its ExcitePCR Corporation subsidiary, is developing the FireflyDX family of products, automated pathogen detection systems for rapid diagnostics at the point-of-care/point-of-need ("POC/PON"). The FireflyDX family products, consisting of the FireflyDX-Portable™ and the FireflyDX-Handheld™, are designed to be lab quality, real-time devices able to detect pathogens faster and less expensively than existing systems. FireflyDX's applications include POC/PON detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.